Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
16.26
+0.23 (1.47%)
Oct 8, 2025, 9:56 AM EDT - Market open
Spyre Therapeutics Employees
Spyre Therapeutics had 65 employees as of December 31, 2024. The number of employees increased by 35 or 116.67% compared to the previous year.
Employees
65
Change (1Y)
35
Growth (1Y)
116.67%
Revenue / Employee
n/a
Profits / Employee
-$2,488,000
Market Cap
981.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Dec 31, 2021 | 101 | 11 | 12.22% |
| Dec 31, 2020 | 90 | 14 | 18.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SYRE News
- 3 days ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire
- 19 days ago - Intelligent Development Could Make Spyre Therapeutics Best In Show - Seeking Alpha
- 4 weeks ago - Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward - Seeking Alpha
- 4 months ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PRNewsWire
- 4 months ago - Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 - PRNewsWire